Document 0050
 DOCN  M9470050
 TI    [Primary and secondary prevention of Pneumocystis carinii pneumonia with
       pentamidine aerosol. Effectiveness, side effects and incidence of
       extrapulmonary Pneumocystis carinii manifestations]
 DT    9409
 AU    Stoehr A; Plettenberg A; Albrecht H; Stellbrink HJ; Meigel W; Begemann
       F; Allgemeines Krankenhaus St. Georg, Interdisziplinare; HIV-Ambulanz
       Hamburg.
 SO    Med Klin. 1994 Mar 15;89(3):132-5. Unique Identifier : AIDSLINE
       MED/94254759
 AB    BACKGROUND: We report on a retrospective study in 544 HIV-positive
       patients, (42 women, 502 men, mean age 35 years) showing CD4 lymphocyte
       counts below 200 c/mcl or after their cure of Pneumocystis carinii
       pneumonia, who received 300 mg pentamidine aerosol as prophylaxis
       against Pneumocystis carinii pneumonia every four week. PATIENTS AND
       METHODS: 277 patients were asymptomatic, 120 in the AIDS related complex
       stage (ARC) and 147 in the full stage of AIDS. The mean follow-up was
       14.4 months. RESULTS: A total of 25 cases of Pneumocystis carinii
       pneumonia was observed (3.83/year): in the primary prophylaxis group 18
       (3.25%/year), in the secondary prophylaxis group seven (6.8%/year). By
       introducing the loading dose (one inhalation per day for five
       consecutive days for patients with CD4 cell counts below 150 c/mcl) we
       reduced the percentage of early manifestations within the first three
       months from 61% to 14%. No extrapulmonary Pneumocystis carinii
       manifestation was observed. CONCLUSION: This study supports the efficacy
       of pentamidine aerosol prophylaxis of primary and secondary Pneumocystis
       carinii pneumonia.
 DE    Administration, Inhalation  Adult  Aerosols  AIDS-Related Opportunistic
       Infections/*PREVENTION & CONTROL  English Abstract  Female  Follow-Up
       Studies  Human  Male  Middle Age  Pentamidine/*ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS  Pneumonia, Pneumocystis carinii/*PREVENTION &
       CONTROL  Recurrence  Retrospective Studies  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).